Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro

Core Viewpoint - Eli Lilly is suing two pharmacies for allegedly compounding its drugs Zepbound and Mounjaro, claiming these pharmacies are violating FDA regulations and diverting customers from its FDA-approved products [1][2]. Group 1: Legal Actions - Eli Lilly has filed lawsuits against Strive Pharmacy and Empower Pharmacy in Delaware and New Jersey [2]. - The lawsuits allege that the pharmacies are falsely marketing their compounded drugs as personalized versions of Lilly's clinically tested medications [2]. Group 2: FDA Regulations - The FDA had previously determined that there was no longer a shortage of Lilly's branded drugs, which led to a ban on compounding pharmacies making their own versions of tirzepatide, the active ingredient in Zepbound and Mounjaro [3]. - Despite the FDA's ruling, some compounding pharmacies continued to produce their versions by altering dosages and combining them with vitamins, potentially evading the FDA's ban [3].